TD Private Client Wealth LLC Boosts Stock Holdings in Becton, Dickinson and Company $BDX

TD Private Client Wealth LLC grew its position in Becton, Dickinson and Company (NYSE:BDX) by 88.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,661 shares of the medical instruments supplier’s stock after acquiring an additional 6,417 shares during the quarter. TD Private Client Wealth LLC’s holdings in Becton, Dickinson and Company were worth $2,557,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BDX. Bill Few Associates Inc. grew its holdings in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 55 shares in the last quarter. Gilbert & Cook Inc. lifted its stake in Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 56 shares in the last quarter. Mendel Money Management boosted its holdings in shares of Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after purchasing an additional 58 shares during the last quarter. Focus Financial Network Inc. grew its position in shares of Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after purchasing an additional 58 shares in the last quarter. Finally, Moody National Bank Trust Division increased its holdings in shares of Becton, Dickinson and Company by 2.4% in the second quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after purchasing an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 0.7%

Becton, Dickinson and Company stock opened at $201.38 on Wednesday. The company has a market capitalization of $57.37 billion, a PE ratio of 34.54, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a 50 day moving average price of $194.06 and a 200 day moving average price of $188.80.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. During the same period last year, the business posted $3.81 earnings per share. The company’s quarterly revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were given a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Bank of America raised their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada upped their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $207.64.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This trade represents a 4.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 1,052 shares of company stock valued at $201,235. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.